[go: up one dir, main page]

DK0610345T3 - Kombinerede cellulære og immunosuppressive terapier - Google Patents

Kombinerede cellulære og immunosuppressive terapier

Info

Publication number
DK0610345T3
DK0610345T3 DK92922624T DK92922624T DK0610345T3 DK 0610345 T3 DK0610345 T3 DK 0610345T3 DK 92922624 T DK92922624 T DK 92922624T DK 92922624 T DK92922624 T DK 92922624T DK 0610345 T3 DK0610345 T3 DK 0610345T3
Authority
DK
Denmark
Prior art keywords
cells
foreign
immunosuppressive therapies
combined cellular
reduced
Prior art date
Application number
DK92922624T
Other languages
Danish (da)
English (en)
Inventor
A Sherwin Stephen
B Dubridge Robert
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Application granted granted Critical
Publication of DK0610345T3 publication Critical patent/DK0610345T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK92922624T 1991-10-21 1992-10-14 Kombinerede cellulære og immunosuppressive terapier DK0610345T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78107591A 1991-10-21 1991-10-21
PCT/US1992/008969 WO1993007887A1 (fr) 1991-10-21 1992-10-14 Therapies cellulaires et immuno-suppressives combinees

Publications (1)

Publication Number Publication Date
DK0610345T3 true DK0610345T3 (da) 2000-10-23

Family

ID=25121603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92922624T DK0610345T3 (da) 1991-10-21 1992-10-14 Kombinerede cellulære og immunosuppressive terapier

Country Status (11)

Country Link
US (1) US5670148A (fr)
EP (1) EP0610345B1 (fr)
JP (1) JPH07500343A (fr)
AT (1) ATE194494T1 (fr)
AU (1) AU2883192A (fr)
CA (1) CA2121487A1 (fr)
DE (1) DE69231250T2 (fr)
DK (1) DK0610345T3 (fr)
ES (1) ES2150424T3 (fr)
GR (1) GR3034510T3 (fr)
WO (1) WO1993007887A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US6063375A (en) * 1996-09-10 2000-05-16 Medical University Of South Carolina Semiallogeneic cell hybrids and related methods for treating cancer
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
AU741602B2 (en) * 1998-02-02 2001-12-06 Johns Hopkins University School Of Medicine, The A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
AU2007229367B2 (en) * 1999-06-25 2011-02-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem In Vitro Micro-Organs and Uses Related Thereto
AU2003271042C1 (en) * 1999-06-25 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem In Vitro Micro-Organs and Uses Related Thereto
US20060127366A1 (en) * 1999-06-25 2006-06-15 Mitrani Eduardo N Method and device for inducing biological processes by micro-organs
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
US7468242B2 (en) 2001-11-05 2008-12-23 Medgenics, Inc. Dermal micro organs, methods and apparatuses for producing and using the same
US8088568B2 (en) 2001-11-05 2012-01-03 Medgentics, Inc. Dermal micro-organs, methods and apparatuses for producing and using the same
US8501396B2 (en) 2001-11-05 2013-08-06 Medgenics Medical Israel Ltd. Dermal micro-organs, methods and apparatuses for producing and using the same
EP2377404A1 (fr) 2003-05-01 2011-10-19 Medgenics, Inc. Micro-organe dermique qui est un explant de tissus vivants
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
US9127084B2 (en) 2006-09-14 2015-09-08 Medgenics Medical Israel Ltd. Long lasting drug formulations
KR101470472B1 (ko) 2006-09-14 2014-12-09 메드제닉스 메디칼 이스라엘 리미티드 장기 지속형 약물 제형
US9731023B2 (en) 2010-09-08 2017-08-15 Board Of Regents, The University Of Texas System Somatostatin receptor-based cancer therapy
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
EP3579870A4 (fr) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Agents de ciblage de tumeur à lymphocytes t car (ctct) d'éther de phospholipide (ple)
WO2018160622A1 (fr) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions et méthodes de thérapie par lymphocytes t car
AU2019209432A1 (en) 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
WO2019165237A1 (fr) 2018-02-23 2019-08-29 Endocyte, Inc. Procédé de séquençage pour thérapie par lymphocytes t à car

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769317A (en) * 1983-06-14 1988-09-06 Hefton John M Process for growing human epidermis, product thereof
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5175004A (en) * 1988-12-27 1992-12-29 Matsumura Kenneth N Propagatable, new combinant cells for cellular replacement therapy
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
EP0591462B1 (fr) * 1991-07-15 2003-04-16 Oklahoma Medical Research Foundation Cellules donneuses universelles

Also Published As

Publication number Publication date
ATE194494T1 (de) 2000-07-15
EP0610345A1 (fr) 1994-08-17
ES2150424T3 (es) 2000-12-01
DE69231250D1 (de) 2000-08-17
DE69231250T2 (de) 2001-03-15
US5670148A (en) 1997-09-23
CA2121487A1 (fr) 1993-04-29
EP0610345B1 (fr) 2000-07-12
AU2883192A (en) 1993-05-21
WO1993007887A1 (fr) 1993-04-29
GR3034510T3 (en) 2000-12-29
EP0610345A4 (fr) 1997-01-15
JPH07500343A (ja) 1995-01-12

Similar Documents

Publication Publication Date Title
DK0610345T3 (da) Kombinerede cellulære og immunosuppressive terapier
AU2953895A (en) Multi-stage cascade boosting vaccine
DK66692D0 (da) En mammal cytokin, il-11
ATE198621T1 (de) Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28
NZ506214A (en) Therapy for alpha-galactosidase A deficiency
IT1170235B (it) Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare
FR2709309B1 (fr) Compositions cellulaires, préparation et utilisations thérapeutiques.
DK0714444T3 (da) Dæmpning af en immundominant epitop i et antigen til anvendelse i plante-, dyre- og humanvacciner og immunbehandlinger
EA199800272A1 (ru) Фактор, стимулирующий дендритные клетки
DK0668772T3 (da) Specifik immunsystemmodulering
DE69110877D1 (de) Idiotypen-impfung gegen b-zell-lymphoma.
MY116474A (en) Potentiation of temozolomide in human tumour cells
ES2093607T3 (es) Rna bicatenario para la correccion de anomalias en complejos inmunes circulantes y en la funcion de los monocitos.
NO890046D0 (no) Disubstituerte pyridiner.
ATE285247T1 (de) Krebstherapie mit lymphotoxin
ATE226087T1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
USD183009S (en) Chair
GB696197A (en) Improvements relating to shelf construction
HOFMANN G. DONALD WHEDON
Walsh et al. Further studies on in vitro suppression of rotavirus using a purified fraction of bovine lecithin.
IT1253656B (it) Perfezionata custodia di bilie per giochi di biliardo o simili che puo' chiudersi solo se tutte le bilie vengono rimesse nella medesima
AR019100A1 (es) Administracion de proteinas terapeuticas
FUKUSHIMA My Polysaccharide Therapy of Haman Cancer and the Study on Polysaccharide by Hamashima et al
陳五福 Blind children's psychomotility and rehabilitation